Kidney Toxicogenomics of Chronic Potassium Bromate Exposure in F344 Male Rats

David R. Geter\(^1,3\), William O. Ward\(^1\), Geremy W. Knapp\(^1\), Anthony B. DeAngelo\(^1\), Jessica A. Rubis\(^2\), Russell D. Owen\(^1\), James W. Allen\(^1\) and Don A. Delker\(^1,7\)

\(^1\)National Health and Environmental Effects Research Laboratory, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC 27711.
\(^2\)CIIT Centers for Health Research, Research Triangle Park, NC 27711.
\(^3\)National Exposure Research Laboratory, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, NC 27711.

Abstract

Background: Potassium bromate (KBrO\(_3\)), used in both the food and cosmetics industry, and a drinking water disinfection by-product, is a nephrotoxic compound and rodent carcinogen. To gain insight into the carcinogenic mechanism of action and provide possible biomarkers of KBrO\(_3\) exposure, the gene expression in kidneys from chronically exposed male F344 rats was investigated.

Methods: Male F344 rats were exposed to KBrO\(_3\) in drinking water for 52 and 100 wk. Kidneys were removed, frozen, and stored at \(\sim\)80ºC, then used for Affymetrix microarray analysis. Gene expression patterns were examined using a non-carcinogenic (20 ppm) and carcinogenic dose (400 ppm) at 52 wk, and compared to 100 wk high dose (400 ppm) and adenoma gene expression.

Results: Statistical analysis revealed 144, 224, 43, and 994 genes out of 15866 from the 52 wk low, 52 wk high, 100 wk high, and adenomas respectively, were differentially expressed when compared to control kidneys. Gene ontology classification of the 52 wk high dose showed alterations of gene transcripts involved in oxidative stress, lipid metabolism, kidney function/ion transport, and cellular function. In a comparison of kidney development gene expression, alterations were seen in the adenomas but not in the 52 wk bromate-treated kidneys. However, the normal kidney from the high dose group resembled the adenoma expression pattern with early kidney development genes being up-regulated and adult phase genes being down-regulated. Moreover, eight genes were identified which could serve as biomarkers of carcinogenic exposure to bromate. The most promising of these was Pendrin, or Slc26a4, a solute carrier of chloride and iodide active in the kidney, thyroid, and inner ear. All these tissues are targets of KBrO\(_3\) toxicity. Expression array results were verified with quantitative real-time rtPCR.

Conclusions: These data demonstrate that the 400 ppm carcinogenic dose of KBrO\(_3\) showed marked gene expression differences from the 20 ppm non-carcinogenic dose. Comparison of kidney development gene expression showed that the adenoma patterns were more characteristic of embryonic than adult kidneys, and that the normal kidney from the high dose group resembled the adenoma-like gene expression pattern. Taken together, the analysis from this study identifies potential biomarkers of exposure and illuminates a possible carcinogenic mode of action for KBrO\(_3\).

Abbreviations: CD: collecting duct, DBPs: disinfection by-products, DCT: distal convoluted tubules, DEG: differently expressed genes, K: potassium, KBrO\(_3\): potassium bromate, LH: loop of Henle, ppm: part per million, PCT: proximal convoluted tubules, QRT-rtPCR: Quantitative Real Time-rtPCR, THMs: trihalomethanes.

Keywords: drinking water, bromate, disinfection by-product, gene expression, biomarker.

Background

The disinfection of public drinking water over the past century has dramatically decreased infectious waterborne diseases and is a hallmark of American public health policy. The benefits of drinking water disinfection are well recognized, however, an undesirable side effect is the production of disinfection by-products (DBPs). These DBPs are formed when disinfectants such as chlorine, chloramine, and ozone react with organic and inorganic matter in water. In the mid 1970’s, it was discovered that...
Trihalomethanes (THMs) were produced in chlorination of drinking water and that they are carcinogenic in laboratory animals (Rook, 1974; Bellar et al. 1974; NCI, 1976). Because of the potential health risks associated with THMs, in 1979 the U.S. Environmental Protection Agency (U.S. EPA) began the regulation of DBPs in the water supply. Initially, concern focused on the trihalomethanes (THMs), but it is now recognized that a wide variety of DBPs are produced during chlorination.

In an effort to reduce exposure to halogenated DBPs, many utilities have switched to ozonation as an alternative treatment method to chlorination. Ozonation is also preferred because it reduces the turbidity of the water and is effective in treating chlorine resistant organisms. However, if ozonation is performed using surface water high in bromide content, brominated by-products, such as bromate ion (BrO$_3^-$), can be generated (Fiessinger et al. 1985). Potassium bromate (KBrO$_3$), a salt of the bromate ion, is nephro- and neurotoxic in humans and carcinogenic in rodents (IARC, 1986; Kurokawa et al. 1990). Under the current guidelines for cancer risk assessment (U.S. EPA, 1986), bromate is classified as a probable human carcinogen due to its kidney carcinogenicity in male and female rats following exposure in drinking water (Kurokawa et al. 1983, 1986a, 1986b; DeAngelo et al. 1998; Wolf et al. 1998). A dose-response relationship in rat kidneys was observed in progressive severity from renal dysplastic foci, preneoplastic lesions, through renal adenomas, and finally renal carcinoma (Kurokawa et al. 1986a; DeAngelo et al. 1998; Wolf et al. 1998).

Mechanistic studies by Umemura et al. (2004, 2006) demonstrated dose-dependent changes in oxidative stress and cell proliferation parameters at carcinogenic doses of potassium bromate in male and female rat kidneys. After four weeks of continuous drinking water exposure, 8-oxodeoxyguanosine levels (8-oxodG), an indicator of pro-mutagenic oxidative DNA damage (Wood et al. 1990; Shibutani et al. 1991), were significantly elevated in male and female rats administered potassium bromate at concentrations of 250 ppm and higher. In addition, BrdU labeling, an indicator of cell proliferation, was also increased in the proximal tubule of female rats at similar concentrations and in male rats at concentrations as low as 30 ppm. It was suggested, however, that the susceptibility of the male rat to increased cell proliferation at lower concentrations was probably attributable to increased α2u-globulin in the male rat proximal tubule. These studies provide important information regarding the potential mechanism of action of potassium bromate carcinogenicity.

The primary objective in this study was to examine renal gene expression differences in male F344 rats exposed to a non-carcinogenic and carcinogenic dose (20 and 400 ppm, respectively) of KBrO$_3$ in drinking water for 52 wk. Furthermore, renal gene expression from the high dose (400 ppm) and adenomas from 100 wk exposed animals were examined and compared to the 52 wk exposure groups. This was accomplished by extracting kidney and adenoma RNA from rats exposed in the previous 1998 DeAngelo et al. study. Comparisons of gene expression profiles between these groups were used to identify functional pathways and individual genes that might contribute to the carcinogenic mechanism of action for KBrO$_3$ and provide insight into potential biomarkers of exposure.

**Methods**

**Animal maintenance**

Complete study details were published previously (DeAngelo et al. 1998). Briefly, KBrO$_3$ (99%; CAS 7758–01–2) dissolved in deionized water at concentrations of 0, 20, 100, 200, and 400 ppm was administered to male F344 rats as the sole water source for 12, 26, 52, 78, or 100 wk. Rats, 28 to 30-days-old, were allowed to acclimate for 1 wk and then randomly assigned to treatment groups. Treatment rooms were maintained at 20–22°C and 40–60% humidity with a 12-hr light: dark cycle. Rats were housed 3 per cage on wood chips and provided Purina Rodent Laboratory Chow (St. Louis, MO) and water ad libitum. Animals were observed daily and moribund animals were euthanized and necropsied. Six animals from each group were euthanized by CO$_2$ asphyxiation and necropsied after 52 wk of treatment. At necropsy, kidneys were removed, washed, flash frozen in liquid nitrogen, and stored at −80°C.

**Microarray experiment**

For the microarray experiment, rats exposed to 0, 20, and 400 ppm KBrO$_3$ for 52 wk, were selected because they represent a control, non-carcinogenic,
and carcinogenic dose, respectively (DeAngelo et al. 1998; Wolf et al. 1998). Kidneys from animals exposed to 20 and 400 ppm KBrO₃ for 52 wk were compared to kidneys from 52 wk control animals. In addition, kidneys from rats exposed to 0 and 400 ppm KBrO₃ and two adenomas from animals exposed for 100 wk were also examined. For this comparison, kidneys from the 100 wk high dose and adenomas were compared to kidneys from 100 wk control animals. Kidney RNA was extracted from three animals per dose group in the 52 wk exposure, and two animals per dose group in the 100 wk samples. RNA from two 100 wk adenomas were also extracted. RNA extraction was performed by acid guanidinium isothiocynate-phenol-bromochloro propane treatment (Tri reagent; Molecular Research Center, Inc., Cincinnati, OH, U.S.A.) and purified on an affinity resin (RNeasy; Qiagen, Valencia, CA) according to manufacturer instructions. Extractions were tested on an Agilent Bioanalyzer to determine RNA quality. Clearly defined 28S and 18S bands were observed on all samples used for microarray analysis. Samples showing degradation were not used for microarray analysis. Microarray procedures were performed as recommended by the manufacturer of the GeneChip system (Affymetrix, Inc, Santa Clara, CA, U.S.A.). The gene expression probe array used was the Rat Expression Array 230A gene chip containing 15,866 probe sets. For each animal, one kidney sample was used for gene expression analysis. Chips were examined by M versus A plots, chip clustering, and principal component analysis to determine outlying chips. Arrays demonstrating poor hybridization were not used for analysis.

**Data analysis**

The resulting image files (.cel) were normalized using the procedure of Li and Wong [D-chip] (2001a; 2001b) and the determination of significant differences between groups were performed by using the web interface of Cyber-T [http://visitor.ics.uci.edu/genex/cybert/](Baldi and Long, 2001). A tutorial for using both D-chip and Cyber-T, found on the Cyber-T website, was used as the procedure for this analysis. Multiple testing correction and false discovery rate test were conducted by using the method of Benjamini and Hochberg (1995) on P-values: $P = < (i/m)q$, where $i$ = # of genes accepted at selected $p$, $m$ = total # genes, and $q$ = desired false discovery rate. Determination of false positives was performed by: $fp = (Pbh * total \#\ genes)$. This resulted in a unique P-value for each comparison. Genes expressed at levels different than control such that a corrected P-value less than 0.05 were classified as differentially expressed genes (DEG) and annotated using NetAffx (http://www.affymetrix.com). Individual literature review on each DEG was conducted and used to classify genes into functional groups.

**Kidney developmental gene response in KBrO₃ induced adenoma**

Gene expression analysis has become sufficiently standardized that comparisons between experimental datasets can yield insights into biological processes such as the differentiation of renal cells. In this vein, we compared our dataset of gene expression in whole adult rat kidney to that collected and analyzed by Stuart et al. (2001). This study performed the first high density oligonucleotide microarray investigation of kidney development using the 8,740 gene Affymetrix rat U34A microarray. Multiple developmental stages were examined, including embryonic day 13 (E13), E15, E17, E19, newborn, 1 wk, and adult. Cluster analysis defined five temporal expression groups. Early group consisted of genes with very high expression in the early embryonic kidney, many with roles in protein translation and DNA replication. Prenatal group consisted of genes that peaked in mid-embryogenesis and contained many transcripts specifying proteins of the extracellular matrix. Neonatal group consisted of transcripts that peaked in the neonatal period and contained a number of retrotransposon RNAs. Steady group contained genes that steadily increased in relative expression levels throughout development, including many genes involved in energy metabolism and ion and water transport. Adult group consisted of genes with relatively low levels of expression throughout embryogenesis but with markedly higher levels in the adult kidney; this group included a heterogeneous mix of transporters, detoxification enzymes, and oxidative stress genes.

Lists of the five groups of genes identified in Stuart et al. (2001), were obtained from the supplemental data website (http://organogenesis.ucsd.edu/). These gene-lists used U34A probe set
identifiers. We determined the Rat Expression Array 230A probe set identifiers that corresponded to the U34A probe sets using the best match comparison file from Affymetrix. For the five kidney development groups mentioned above, there were 838, 168, 61, 510, and 193 genes located on the U34 array and 676, 126, 42, 428, and 155 genes located on the Rat Expression Array 230A array. The minimum sequence identity for a given probe set between the U34A and Rat Expression Array 230A array was 93% and the average identity was greater than 99%. For each group, the genes that were identified in the Affymetrix best match comparison file constituted the gene members for that group in subsequent analysis.

Real time PCR determination of gene expression
Quantitative real-time rtPCR (QRT-rtPCR) data was collected from fresh aliquots of the total RNA samples used to obtain array data. On average, 85 ng of total RNA was loaded in a one-step QRT-rtPCR reaction. Multiscribe reverse transcriptase was used to generate the cDNA template followed by amplification with AmpliTaq Gold DNA polymerase (Applied Biosystems). Target specific assays were either custom designed or purchased from Applied Biosystems’ TaqMan Assays on Demand. All reactions were performed according to manufacturer’s procedures. The QRT-rtPCR cycling parameters were: 48ºC, 45 min cDNA synthesis; 95ºC, 10 min AmpliTaq Gold (Applied Biosystems) activation; and 40 cycles of amplification at 94ºC, 15 sec melting followed by 60ºC, 1 min annealing/extension. Reaction volumes totaled 20 μl and were run in triplicate in 384 well plates on an ABI prism 7900HT. Based on the array data, Rpl27 (ribosomal protein L27) was chosen as a reference gene since it exhibited no differential gene expression across treatment groups and showed similar expression levels to the genes of interest. Confirmation that Rpl27 was not differentially expressed across treatment groups was confirmed by QRT-rtPCR analysis (data not shown).

Results

Microarray analysis
The results of the statistical comparison among tissues from the 52 wk control, low, and high dose groups, and the 100 wk control, high, and adenoma groups are given in Table 1. This study has been archived in ArrayExpress under accession number E-T0XM-21.

Analysis of gene expression
Gene ontology (GO) analysis of DEG expression in the kidney from male F344 rats exposed to low (20 ppm) and high (400 ppm) KBrO₃ for 52 wk are shown in Table 2. The individual functional group information composed of gene symbol and name, Affymetrix and accession numbers, and fold change are given for oxidative stress (Table 3), and kidney function / ion transport (Table 4) genes. In addition to the above mentioned groups, a large amount of lipid metabolism, oxidoreductase, and cellular function genes were observed and are shown as additional files: "lipid metabolism table.pdf, oxidoreductase table.pdf and cellular function table.pdf. “ A total of 99 and 139 genes were used to provide an interpretive basis for differences in

| Treatment                  | Genes < 0.01 | P-value     | False Positives | Differentially Expressed | Annotated |
|----------------------------|--------------|-------------|-----------------|--------------------------|-----------|
| 52 wk low (3)*             | 470          | 0.00128     | 21              | 144                      | 99        |
| 52 wk high (3)             | 603          | 0.00189     | 30              | 224                      | 139       |
| 100 wk high (2)            | 244          | 0.000766    | 13              | 43                       | 27        |
| 100 wk adenomas (2)        | 1431         | 0.0045      | 72              | 994                      | 671       |

* The sample size for the comparison is shown with the treatment group.
expression that were observed in the kidneys of rats treated with non-carcinogenic and carcinogenic doses, respectively.

Analysis of the low dose showed a general suppression of gene expression with 71% of genes down-regulated relative to control tissues compared to 56% in the high dose. The most notable down-regulated groups in the low dose were oxidative stress and kidney function with 100% and 77% down-regulated, respectively. In the high dose, 87% of genes in kidney function and 90% of genes in lipid metabolism groups were down-regulated. Overall these changes suggest a general suppression of gene expression in the low dose group, especially those genes involved in oxidative stress and kidney function. This is in contrast to the high dose, where kidney function and lipid metabolism genes are suppressed in concert with an increased amount of oxidative stress related genes.

A comparison of genes whose expression was significantly altered in the 52 wk high dose (400 ppm) and the 100 wk adenomas is given as an additional file: “similar 52,100, adenomas.pdf.” In this comparison, 35 genes were down-regulated relative to the kidney of control animals, 3 were

Table 2. Gene ontology (GO) analysis of differentially expressed genes (DEG) in kidneys from male rats exposed to 20 ppm (low) and 400 ppm (high) potassium bromate in drinking water for 52 wk. Results are the number of differentially expressed genes within a functional group that were either up or down regulated, with group total. Functional analyses for all groups were compiled by individual gene review.

| Functional Group*       | Control versus Low | Control versus High |
|-------------------------|--------------------|---------------------|
|                         | Down | Up  | Total | Down | Up  | Total |
| Oxidative Stress        | 4    | 0   | 4     | 5    | 5   | 10    |
| Lipid Metabolism        | 6    | 4   | 10    | 9    | 1   | 10    |
| Kidney Function         | 10   | 3   | 13    | 20   | 3   | 23    |
| Oxidoreductase          | 10   | 1   | 11    | 13   | 0   | 13    |
| Cell Function           | 30   | 10  | 40    | 20   | 22  | 42    |

*A total of 99 and 139 genes were used for gene ontology analyses from low and high exposure concentrations respectively.

Table 3. List of differentially expressed oxidative stress genes in kidney from male rats exposed to 20 ppm (low) and 400 ppm (high) potassium bromate in drinking water for 52 wk. All comparisons were made between the specific treatment group and their corresponding control.

| Gene Symbol | Gene Name | Affymetrix No. | Accession No. | Fold Change |
|-------------|-----------|----------------|---------------|-------------|
| Low dose    |           |                |               |             |
| Dscr1       | Down syndrome critical region homolog 1 | 1388686_at | NM_153724    | –1.4        |
| Hspb1       | Heat shock protein                      | 1367577_at | NM_031970    | –1.5        |
| Txnrd1      | Thioredoxin reductase 1                 | 1386958_at | NM_031614    | –1.4        |
| Xdh         | Xanthine dehydrogenase                  | 1369973_at | NM_017154    | –1.4        |
| High dose   |           |                |               |             |
| Dscr1       | Down syndrome critical region homolog 1 | 1388686_at | NM_153724    | –1.3        |
| Gnmnt       | Glycine N-methyltransferase             | 1387672_at | NM_017084    | –1.3        |
| Gsta2       | Glutathione S-transferase A2            | 1368180_at | NM_017013    | –1.2        |
| Hspbap1     | Heat shock associated protein           | 1368195_at | NM_134419    | –1.8        |
| Pex11a      | Peroxisomal biogenesis factor 11a       | 1379361_at | NM_053487    | –1.3        |
| Ccng1       | Cyclin G1                               | 1367764_at | NM_012923    | 1.3         |
| Cp          | Ceruloplasmin (ferroxidase)             | 1368418_at | NM_012532    | 1.3         |
| Gclm        | Glutamate-cysteine ligase, modifier subunit | 1370030_at | NM_017305    | 1.3         |
| Gstm1       | Glutathione S-transferase M 1           | 1386985_at | NM_017014    | 1.4         |
| Gstp1       | Glutathione S-transferase Pi 1          | 1388122_at | NM_012577    | 1.3         |

*a Gene symbols and accession numbers from Affymetrix NetAffx (http://www.affymetrix.com/analysis/index.affx).
### Table 4. List of differentially expressed kidney function/ion transport genes in kidney from male rats exposed to 20 ppm (low) and 400 ppm (high) potassium bromate in drinking water for 52 wk. All comparisons were made between the specific treatment group and their corresponding control.

| Gene Symbol | Gene Name                   | Affymetrix No. | Accession No. | Fold Change |
|-------------|------------------------------|----------------|---------------|-------------|
| Low dose    |                              |                |               |             |
| Aqp1        | Aquaporin 1                  | 1387651_at     | NM_012778     | -1.3        |
| Atp1a1      | ATPase, Na+/K+ transporting, alpha 1 | 1371108_a_at   | NM_012504     | -1.2        |
| Dscr1       | Down syndrome critical region homolog 1 | 1388686_at     | NM_153724     | -1.4        |
| G6pc        | Glucose-6-phosphatase,       | 1386944_a_at   | NM_013098     | -1.7        |
| Ramp3       | Receptor (calcitonin) activity modifying protein 3 | 1387389_at     | NM_020100     | -1.9        |
| Sgk         | Serum/glucocorticoid regulated kinase | 1367802_at     | NM_019232     | -1.6        |
| Slc15a1     | Solute carrier family 15, member 1 | 1369381_a_at   | NM_057121     | -1.5        |
| Slc16a1     | Solute carrier family 16, member 1 | 1386981_at     | NM_012716     | -2.8        |
| Slc22a1     | Solute carrier family 22, member 1 | 1368191_a_at   | NM_012697     | -1.5        |
| Xdh         | Xanthine dehydrogenase       | 1369973_at     | NM_017154     | -1.4        |
| Calca       | Calcitonin/calcitonin-related polypeptide, alpha | 1370775_a_at   | NM_017338     | 1.4         |
| Cldn16      | Claudin 16                   | 1369184_at     | NM_131905     | 1.4         |
| Slc21a4     | Kidney specific organic anion, scf 21, member 4 | 1368498_a_at   | NM_030837     | 1.4         |
| High dose   |                              |                |               |             |
| Aqp2        | Aquaporin 2                  | 1368568_at     | NM_012909     | -1.4        |
| Aqp3        | Aquaporin 3                  | 1387100_at     | NM_031703     | -1.4        |
| Calb1       | Calbindin 1                  | 1370201_at     | NM_031984     | -1.3        |
| Clcnk11     | Chloride channel K1-like     | 1388175_at     | NM_173150     | -1.4        |
| Dscr1       | Down syndrome critical region homolog 1 | 1388686_at     | NM_153724     | -1.4        |
| Edn1        | Endothelin 1                 | 1369519_at     | NM_012548     | -1.4        |
| Kcnj16      | Potassium inwardly-rectifying channel, J16 | 1373991_at     | AI41366       | -1.2        |
| Kcnq1       | Potassium voltage-gated channel, KQT-like 1 | 1368371_at     | NM_032073     | -1.4        |
| Ngf9        | Nerve growth factor, gamma subunit | 1367961_at     | NM_031523     | -1.9        |
| Prkwnk4     | Protein kinase, lysine deficient 4 | 1389662_at     | NM_175579     | -1.6        |
| Scnn1a      | Sodium channel nonvoltage-gated 1A | 1387104_at     | NM_031548     | -1.3        |
| Scnn1g      | Sodium channel nonvoltage-gated 1G | 1370481_at     | NM_017046     | -1.5        |
| Slc5a2      | Solute carrier family 5, member 2 | 1368414_at     | NM_022590     | -1.4        |
| Slc9a3      | Solute carrier family 9 (Na/H exchanger), isoform 3 | 1387542_at     | NM_012654     | -1.3        |
| Slc12a3     | Solute carrier family 12 (Na/Cl transporters), 3 | 1387230_at     | NM_019345     | -1.4        |
| Slc13a3     | Solute carrier family 13 Na+ transport, member 3 | 1388047_at     | NM_022866     | -1.3        |
| Slc22a5     | Solute carrier family 22, member 5 | 1367950_at     | NM_019269     | -1.3        |
| Slc22a8     | Solute carrier family 22, member 8 | 1368461_at     | NM_031332     | -1.3        |
| Slc26a4     | Pendrin, solute carrier family 26, member 4 | 1368193_at     | NM_019214     | -4.6        |
| Slc37a4     | Solute carrier family 37, member 4 | 1368960_at     | NM_031589     | -1.3        |
| Agtr2       | Angiotensin II receptor, type 2 | 1369711_at     | NM_012494     | 1.5         |
| Cldn16      | Claudin 16                   | 1369184_at     | NM_131905     | 1.6         |
| Cp          | Ceruloplasmin (ferroxidase)   | 1368418_at     | NM_012532     | 1.3         |
| Slc12a1     | Solute carrier family 12 (Na/K/Cl), member 1 | 1368548_at     | NM_019134     | 1.5         |

* Gene symbols and accession numbers from Affymetrix NetAffx (http://www.affymetrix.com/analysis/index.affx).

The table shows that 52/204 genes were down-regulated, and 90 genes did not show the same direction of change. The majority of these down-regulated genes were associated with kidney function.

A common list of genes whose expression was significantly altered relative to control tissue in the 52 wk high (400 ppm), the 100 wk high (400 ppm), and the 100 wk adenoma groups is given in Table 5. In most cases, the magnitude of fold change increases with duration of exposure and/or in tumor tissue. These genes may represent potential biomarkers of bromate exposure and effect.
because the magnitude of their alteration is time-dependent and/or a larger number of renal cells incorporate these transcript changes with continued exposure. Since tumor tissue is theoretically the product of clonal expansion of target cells, these eight genes might also aid in the development of useful tumor markers of KBrO$_3$ carcinogenicity. These genes were: *Calb*$_1$ (Calbindin 1), *Gp*$_2$ (Glycoprotein 2), *Klk*$_7$ (Kallikrein 7), an EST (LOC362802), *Ngfg* (Nerve growth factor, gamma), *Prps*$_2$ (Phosphoribosyl pyrophosphate synthetase 2), *Slc*$_{12}a$_3 (Solute carrier family 12, member 3), and *Slc*$_{26}a$_4 (Solute carrier family 26, member 4).

**Kidney developmental gene response in KBrO$_3$ induced adenoma**

The processes involved in organ development, including cell proliferation, apoptosis, cell adhesion, and differentiation, are processes that are disregulated during carcinogenesis. Therefore, a comparison was made between a previous gene expression profile observed in rat kidney development to that of the kidney adenoma profile from this study. Stuart et al. (2001) identified five groups of genes whose expression characterized stages of rat kidney development. As described in the Methods, genes were identified in the current study that matched specific development groups. Figure 1A shows the average fold change of each group compared to control for low bromate, high bromate and adenoma. Early and prenatal genes, associated with cell proliferation and laying down the extracellular matrix, are up-regulated in the adenoma. Steady and adult genes, associated with energy metabolism, transport, detoxification, and oxidative stress response, are down-regulated in the adenoma. This adenoma expression profile shows the up-regulation of genes prevalent in early kidney development and down-regulation of adult stage genes. This observation is in agreement with the proliferation and de-differentiation profiles seen in classical tumor development.

**Adenoma expression profile resemble high dose bromate kidney**

The adenoma demonstrated an expression profile for kidney development gene groups early, prenatal, steady, and adult that was distinct from control and bromate treated kidneys. In order to determine if the adenoma profile, as determined above, was present in part, in either the low or high KBrO$_3$ exposed animals, the top ten DEGs were selected from each of the four groups mentioned above. Figure 1B shows the average fold change of each group compared to control for low and high dose bromate. This figure illustrates that the high dose kidney, but not the low, did resemble the adenoma expression pattern with the early and prenatal phase genes being up-regulated and the steady and adult phase genes being down-regulated.

**Real time PCR determination of gene expression**

Quantitative Real Time rtPCR assays were conducted to verify gene expression of genes deemed biologically relevant based on pathway

| Gene Symbol | Affymetrix No. | Accession No. | 52 wk High Dose Fold Change | 100 wk High Dose Fold Change | Adenoma Fold Change |
|-------------|---------------|---------------|-----------------------------|-----------------------------|--------------------|
| Calb1       | 1370201_at    | NM_031984     | −1.3                        | −11.4                       | −153.4             |
| Gp2         | 1386933_at    | NM_134418     | −2.2                        | −11.9                       | −18.6              |
| Klk7        | 1387820_at    | NM_012593     | −1.4                        | −12.1                       | −57.3              |
| LOC362802   | 1376239_at    | NM_001014199  | −1.9                        | −3.6                        | −2.6               |
| Ngfg        | 1367961_at    | NM_031523     | −1.9                        | −20.5                       | −77.3              |
| Prps2       | 1375932_at    | NM_012634     | −1.4                        | −2.9                        | −2.6               |
| S1c12a3     | 1387230_at    | NM_019345     | −1.4                        | −4.8                        | −6.6               |
| S1c26a4     | 1368193_at    | NM_019214     | −4.6                        | −6.0                        | −6.3               |

*Gene symbols and accession numbers from Affymetrix Netaffx (http://www.affymetrix.com/analysis/index.affx).*
Figure 1A. Kidney development gene response in F344 male rats exposed to KBrO₃ in drinking water. Kidney development gene groups were defined in Stuart et al. (2003) and applied to our data as described in the methods section. For each group of genes, the expression was normalized to control and an average response was calculated for: 52 wk low (20 ppm) KBrO₃, 52 wk high (400 ppm) KBrO₃, and 100 wk KBrO₃-induced adenomas. For each group, the average fold change normalized to control was plotted on the y-axis.

Figure 1B. Gene expression pattern in F344 male rats exposed to high KBrO₃ mimics adenoma expression pattern. Kidney development gene groups were defined in Stuart et al. (2003) and applied to our data as described in the methods section. The differentially expressed genes in the 100 wk KBrO₃-induced adenomas were categorized into kidney development groups. The top ten genes from each developmental group were then used in the 52 wk low (20 ppm) and high (400 ppm) KBrO₃ exposed animals. For these 50 genes, the high exposure group showed a similar expression pattern to the adenomas across kidney development groups.
analysis and genes that could possibly be used as biomarkers of exposure. Figure 2 shows that QRT-rtPCR results confirmed the expression patterns of the genes tested. However, differences in magnitude of change were observed, for example \(Aqp\)2 shows a \(-1.4\) microarray fold change, but an \(-18.5\) QRT-rtPCR fold change. This discrepancy in the magnitude of fold change between microarray data and rtPCR data has been noted in other genomics studies and may be attributable to the superior utility of the rtPCR procedure in quantifying transcript abundance (Crosby et al. 2000). The specific genes selected, including target sequence are given in additional file: “QRT-rtPCR_table.pdf.”

**Discussion**

In the DeAngelo et al. (1998) and Wolf et al. (1998) studies, male F344 rats exposed to 400 ppm KBrO\(_3\) for 52 wk developed kidney cancer, while those exposed to 20 ppm did not. This study used the same animal kidneys from that study to determine if a difference in gene expression could be discerned between the two doses. Examining global gene expression for each dose allowed categorizing of genes into the following groups; oxidative stress, lipid metabolism, kidney function/ion transport, cellular function, and oxidoreductase function.

**Oxidative stress response**

Reactive oxygen species (ROS) are natural by-products produced by the metabolism of \(O_2\) during aerobic respiration. Oxidative stress occurs when there are increases in ROS production, and/or depressed antioxidant defense. Glutathione (GSH) is an important component of the antioxidant and detoxification systems in most tissues. However, under normal cellular conditions, KBrO\(_3\) induces oxidative DNA damage in the form of 8-oxodeoxyguanosine (8-oxodG) that is dependent on GSH and other sulfhydryls (Ballmaier and Epe, 1995; Murata et al. 2001). Bromate-induced oxidative DNA damage is caused by the reduction of bromate to bromine oxides and bromine radicals generated by sulfhydryls like GSH. *In vivo*, it has been suggested that sulfhydryls, present at the brush borders of the proximal convoluted tubule (Zager and Burkhart, 1998), are important in the generation of bromine oxides and bromine radicals (Murata et al. 2001). The relative reduction of extracellular and intracellular bromate and its metabolites also

---

![Figure 2. Affymetrix array and QRT-rtPCR fold-change results of select kidney genes of interest from male F344 rats exposed to 400 ppm KBrO\(_3\) for 52 wk.](image-url)
affect the delivery of bromate ions to target macromolecules. Under high dose conditions, more bromate may be delivered to target cells for intracellular activation due to reduced systemic metabolism and/or antioxidant defenses (Delker et al. 2006). Altered gene expression associated with oxidative stress in the low dose gave only four down-regulated genes Dscr1, Hspb1, Txnrd1, and Xdh. It has been reported that in oxidative stress conditions, Dscr1, Hspb1, and Txnrd1 are elevated (Ermak et al. 2004; Dunlop and Muggli, 2000; Yamawaki and Berk, 2005), and increased levels of Xdh are associated with free radical generation (Sanhueza et al. 1992). Dscr1 is regulated by both oxidative stress and Ca2+ levels (Lin et al. 2003), thus it may be influenced more by Ca2+ ion concentration than oxidative stress. Although these genes are associated with oxidative stress, they are all down-regulated and appear to reflect inhibition, chronic adaptation, or simply no induction of oxidative stress in animals exposed to 20 ppm KBrO3.

A larger involvement of proposed oxidative stress genes are seen in the high dose group with 10 DEG; 5 down- and 5 up-regulated. In the high dose response, the Dscr1 and a heat-shock gene Hspbap1, which are up-regulated in response to ROS, are down-regulated in this study. This is an unexpected response following exposure to a known producer of ROS. However, the expression observed in this experiment is that of a kidney chronically exposed to a carcinogenic dose of KBrO3, and may represent an adaptive gene response. Two additional down-regulated genes, Gnmt and Gsta2, are involved with GSH homeostasis and GSH conjugation, respectively.

The up-regulated oxidative stress genes include Ccng1, Cp, Gclm, and two glutathione transferases, Gstm1 and Gstpl. Studies have demonstrated that cyclin G1 (Ccng1) plays roles in G2/M arrest, damage recovery, and growth promotion after cellular stress (Kimura et al. 2001). Cyclin G1 accomplishes this by regulating the activity of p53 (Jensen et al. 2003). This may indicate possible oxidative stress induced DNA damage followed by increased cellular proliferation. Cp is a plasma protein that is up-regulated in response to oxidative stress and functions as a copper transporter and antioxidant. Gclm is involved in glutathione biosynthesis and is up-regulated as a defensive response to oxidative stress (Mathers et al. 2004).

Two glutathione S-transferases are up-regulated, Gstm1 and Gstpl. Both are involved in the conjugation of reduced GSH to a wide number of exogenous and endogenous hydrophobic electrophiles. Taken together, these data support the finding that KBrO3 does produce an oxidative stress response in the kidney at high doses, however the magnitude of expression was not large, resulting in ten genes with relatively small fold-change. This may be characteristic of a kidney that has developed a resistant morphological phenotype to KBrO3-induced oxidative stress due to long-term chronic exposure.

Lipid metabolism
Altered lipid metabolism and lipid peroxidation have been associated with KBrO3 exposure (Chipman et al. 1998). Cellular fatty acids are readily oxidized by reactive oxygen species to produce lipid peroxyl radicals and lipid hydroperoxides (Rice-Evans and Burdon, 1993). It is generally accepted that oxidative stress can lead to the oxidative degradation of lipids (Moller and Wallin, 1998), which can disrupt normal lipid metabolism. Examination of genes associated with lipid metabolism in the low dose exposure showed 6 down-regulated (Apoet, Cebpb, Chk, Cyp2e1, Cyp4a10, and Fads1) and 4 up-regulated genes (Abcg1, Calca, Gpd2, and Nr1d1). The down-regulated genes dealt primarily with fatty acid metabolism and lipid biosynthesis, while the up-regulated genes were associated with lipid homeostasis and metabolism. In the high dose, nine genes were down-regulated (Acaal2, Acs13, Apoe1, Apom, Cyp2e1, Cyp4a10, Edn1, Ehhadh, Hadhsc), and one up-regulated (Fabp5). These genes were primarily involved in fatty acid and lipid metabolism. Overall, gene expression for lipid metabolism is suppressed, with only one up-regulated gene observed in the high dose, contrary to expectations of KBrO3 induced lipid peroxidation. This is consistent with the work of Umemura et al. (2004) which contained no evidence of lipid peroxidation by chronic treatment of rats with carcinogenic doses of KBrO3.

Kidney function and ion transport
The location of DEG genes involved with kidney function and ion transport within the nephron of the kidney is shown in Figure 3. For the low dose (Fig. 3A), of the 9 genes where specific locations could be identified, 6 were in the proximal conve-
luted tubules (PCT), 2 in the ascending loop of Henle (LH), and 1 in the distal convoluted tubules (DCT). Within the PCT, only the kidney specific organic anion transporter was up-regulated. For the high dose (Fig. 3B), 7 genes were found in the PCT, 4 in the ascending LH, 5 in the DCT, and 6 genes in the collecting duct (CD). All genes in the PCT and CD were down-regulated, whereas Slc12a1 and Cldn16 were up-regulated in the ascending loop and Agtr2 was up-regulated in the DCT. When comparing the low and high figures, the high dose has more altered gene expression in the PCT and significantly more gene involvement down-stream of the PCT with 14 altered genes compared to only 3 in the low. The localized gene expression changes depicted in this figure reinforce the hypothesis that as the KBrO3 dose increases, additional cellular alterations occur in the PCT. As these changes occur, altered gene expression within and down-stream of the PCT is initiated as an attempt to maintain kidney function.

Kidney function and ion transport gene expression in the kidney from the 20 ppm exposure group showed a total of 10 genes down- and 3 up-regulated. Within the down-regulated group were genes mainly dealing with transport of water (Aqp1), sodium (Atp1a1 and Skg), potassium (Atp1a1), glucose (G6pc), and organic cations (Slc22a1). Although Aqp1 was down-regulated, no increase in water consumption was observed. In the up-regulated group were genes involved in calcium homeostasis (Calca), magnesium and calcium transport (Cldn16), and organic anion transport (Slc21a4). These gene expression changes suggest a physiological response that helps maintain electrolyte balance in light of the chronic, low dose KBrO3 exposure. Although the low concentration of KBrO3 used in this study (20 ppm) was not carcinogenic, results from a similar study using a dose of 60 ppm in the drinking water found increased proliferation and mild degeneration of the proximal convoluted tubules (Umemura et al. 2004). However, data collected in this paper indicate that physiological adaptation to KBrO3 exposure is beginning to occur even at a non-carcinogenic dose.

Kidney function and ion transport gene expression in the kidney from the 400 ppm exposure group showed 20 down- and 4 up-regulated genes. Within the down-regulated group were genes involved with transport of water (Aqp2, and Aqp3), calcium (Calb1), chloride (Clenk11 and Prkwnk4, Slc12a3, and Slc26a4), potassium (Kcnj16, Kcnj1, and Prkwnk4), sodium (Ngfg, Prkwnk4, Scnn1a, Scnn1g, Slc5a2, Slc9a3, Slc12a3, and Slc13a3), organic ions (Slc22a5 and Slc22a8), glucose (Slc5a2 and Slc37a4), and regulation of blood pressure (End1). In the up-regulated group were Agtr2, an angiotensin II receptor; Cldn16, a magnesium and calcium transporter (also up-regulated in the low dose); Cp, an iron transporter, and Slc12a1, a sodium, potassium, chloride co-transporter. These results imply significant alterations in the expression of genes involved in kidney function, and possibly decreased organ function.

In this light, when examining the DeAngelo et al. (1998) and Wolf et al. (1998) study, a dose-dependent increase in water consumption was observed starting at wk 4 and continuing through the duration of the study. Overall, it was determined that rats from the high dose (400 ppm) group drank over 30% more than controls. Taken together with the large number of down-regulated kidney function and ion transport genes from the high dose KBrO3 exposure, these data possibly indicate a kidney in chronic renal insufficiency/failure. This condition occurs when the kidneys are unable to conserve water as they perform their blood filtering function. The amount of water conserved is controlled by antidiuretic hormone (ADH), also known as vasopressin. ADH controls kidney osmosis by inserting water pores into the collecting ducts. The water pores, Aqp2 and 3, are responsible for the final adjustment of urine concentration. In the high dose animals, Aqp2 and 3 transcripts are down-regulated. This would result in fewer water pores in the collecting duct leading to increased amounts of dilute urine. With the increase in urine production, the kidney may respond to maintain ionic balance and blood volume by down-regulating the genes contributing to loss of nutrients and electrolytes and up-regulating transporter genes necessary for reabsorption, such as Slc12a1 and Cldn16.

Within the high dose PCT and CD is a down-regulated gene called pendrin, or Slc26a4. Pendrin functions as a sodium-independent transporter of chloride and iodide where it is expressed in kidney, thyroid, and inner ear (Scott et al. 1999; Soleimani et al. 2001). It should be noted that KBrO3, in addition to being a kidney carcinogen, is also a thyroid carcinogen, and can cause deafness (Yoshino et al. 2004). Moreover, pendrin expression was lower in thyroid carcinomas than in normal thyroid tissue.
Figure 3A and 3B. Figure 3A (20 ppm) and 3B (400 ppm) show the location within the kidney nephron of specific genes associated with kidney function from male rats exposed to KBrO₃ for 52 wk. Genes in green and red font are down-regulated and up-regulated respectively.

G: glomerulus, PCT: proximal convoluted tubules, LH: loop of Henle, DCT: distal convoluted tubules, and CD: collecting duct.
(Skubis-Zegadlo et al. 2005; Kondo et al. 2003). Pendrin transcripts examined by QT-rtPCR in this study were not altered in the low dose (20 ppm), suppressed in high dose (400 ppm), and virtually absent in kidney adenomas, mirroring the results seen in the thyroid carcinomas. Due to pendrin already being identified as a biomarker in thyroid carcinogenesis, and its involvement in kidney function following KBrO\textsubscript{3} exposure, we propose this gene as a possible biomarker of carcinogenic KBrO\textsubscript{3} exposure.

**Cellular function**

The primary objective of this study was to determine if a discernable difference in kidney gene expression could be observed between a non-carcinogenic and carcinogenic dose of KBrO\textsubscript{3}. Gene ontology analysis of altered gene expression revealed an accumulation of changes in the following functionally-related categories: cancer, cell cycle, cell death, cell-to-cell signaling and interaction, cellular development, and cellular growth and proliferation. Thus, the genes that fell into these categories were placed into a general cellular functional group for analysis. Within this group were 30 down- and 11 up-regulated genes in the low KBrO\textsubscript{3} exposure group, and 20 down- and 22 up-regulated genes in the high exposure group.

In the low KBrO\textsubscript{3} concentration, the majority of genes associated with cellular function were down-regulated (30 versus 11 up-regulated). Several low dose genes when down-regulated are associated with decreased cell proliferation and apoptosis (Akap12, Arhb, Cebp, Csf2rb, Dusp6, Epim, Gadd45a, Id2, Id3, Igfbp3, Igfbp6, Jun, Pim1, Rgc32, Tieg, and Vegfb). This is countered by only one up-regulated gene Ccnd1 (Cyclin d1), which is associated with increased cell proliferation and apoptosis. From this observation, it appears that the gene expression from the low dose kidney does not support increased levels of cell proliferation similar to the BrdU findings of Umemura et al. (2004) whose no-effect level was 15 mg/L.

The gene expression in the high KBrO\textsubscript{3} concentration was more equally distributed with 22 down- and 20 up-regulated genes. There were 10 genes shared in the cellular function category between the low and high KBrO\textsubscript{3} concentration. These were Cyp2e1, Dscr1, Dsipi, F3, Id2, Igfbp1, Ms4a2, Rgc32, Ptgsd, and Vipr1. All were directionally concordant except for Igfbp1.

In contrast to the low dose, fewer genes were associated with cell proliferation and apoptosis (Ccng1, Eno1, Hrasls3, Id2, Igfbp1, Madh7, and Nupr1). Eno1 and Hrasls3, when down-regulated (Subramanian and Miller, 2000; Feo et al. 2000; Sers et al. 2002), and the up-regulated genes, Nupr1, and Ccng1 promote cellular growth and proliferation. However, Id2 and Madh7 when down-regulated support decreased proliferation (Lasorella et al. 1996; Lallemand et al. 2001). Although there are only a few genes in this group, the majority suggest increased cell proliferation and apoptosis.

**Adenoma comparison**

Stuart et al. (2001) established a benchmark expression profile for normal kidney development. By comparing the gene expression changes in the present study to this profile, expression changes that deviated from normal kidney were detected. In four defined kidney development groups, the 52 wk bromate-treated kidneys did not deviate from normal developmental patterns whereas the adenoma samples did. In these samples, the adenoma expression patterns were more characteristic of embryonic than adult kidneys. Although the bromate-treated kidneys did not show a strong expression pattern that matched the adenoma, the high dose kidney, but not the low, did resemble the adenoma expression pattern with genes prevalent in early kidney development being up-regulated and adult phase genes being down-regulated. This observation is in agreement with the proliferation and de-differentiation profiles seen in classical tumor development. Furthermore, the method of comparing developmental gene expression patterns between tumor and exposed animals could serve as a mechanism to identify biomarkers of tumor initiation.

**Conclusion**

These data suggest the 400 ppm carcinogenic dose of KBrO\textsubscript{3} showed marked gene expression differences from the non-carcinogenic dose. These include gene expression changes in oxidative stress and kidney function/ion transport genes. Comparison of kidney development gene expression showed that the adenoma patterns were more characteristic of embryonic than adult kidneys, and that
the high dose kidney gene expression resembled an adenoma-like expression pattern. Taken together, these analyses from this study identify potential biomarkers of exposure and illuminate a possible carcinogenic mode of action for KBrO3.

Competing Interests
The authors declare that they have no competing interests.

Authors’ Contributions
DG aided in study design, carried out Affymetrix experiments, analyzed data, and wrote the manuscript. WW analyzed adenoma comparison with kidney development genes and aided in manuscript and figure preparation. GK performed QRT-rtPCR experiments and data analysis, and aided in manuscript and figure preparation. JR aided in manuscript and figure preparation. AD, RO, and JA were involved in study design with RO assisting in data analysis. DD was involved in study design, carried out Affymetrix experiments, analyzed data, and aided in manuscript preparation.

Acknowledgements
The authors would like to thank Drs. Chris Corton and Kevin Morgan for their review of this manuscript.

The research described in this article has been reviewed by the Health and Environmental Effects Research Laboratory, United States Environmental Protection Agency, and approved for publication. Approval does not signify that the views of the Agency, nor does mention of trade names or commercial products constitute endorsement or recommendation for use.

References
Baldi, P. and Long, A.D. 2001. A Bayesian framework for the analysis of microarray expression data: regularized t-test and statistical inferences of gene changes. Bioinformatics, 17:509–519.

Ballmaier, D. and Epe, B. 1995. Oxidative DNA damage induced by potassium bromate under cell-free conditions and in mammalian cells. Carcinogenesis, 16(2):335–342.

Bellar, T.A., Lichtenberg, J.J. and Kroner, R.C. 1974. The occurrence of organohalides in chlorinated drinking water. J. Am. Water Works Assoc., 66:703–706.

Benjamini, Y. and Hochberg, Y. 1995. Controlling the False Discovery Rate: a Practical and Powerful Approach to Multiple Testing. J. R. Statist. Soc. B., 57:289–300.

Chipman, J.K., Davies, J.E., Parsons, J.L., Nair, J., O’Neill, G. and Fawell, J.K. 1998. DNA oxidation by potassium bromate: a direct mechanism or linked to lipid peroxidation? Toxicology, 126:93–102.

Crosby, L.M., Hyder, K.S., Deangelis, A.B., Kepler, T.B., Gaskill, B., Benavides, G.R., Yoon, L. and Morgan, K.T. 2000. Morphologic analysis correlates with gene expression changes in cultured F344 rat mesothelial cells. Toxicol. Appl. Pharmacol., 169:205–221.

DeAngelo, A.B., George, M.H., Kilburn, S.R., Moore, T.M. and Wolf, D.C. 1998. Carcinogenicity of potassium bromate administered in the drinking water to male B6CF1 mice and F344/N rats. Toxicol. Pathol., 26:587–594.

Delker, D., Hatch, G., Allen, J., Crisman, B., George, M., Geter, D., Kilburn, S., Moore, T., Nelson, G., Roop, B., Slade, R., Swank, A., Ward, W. and DeAngelo, A. 2006. Molecular biomarkers of oxidative stress associated with bromate carcinogenicity. Toxicology, 221(2–3):158–165.

Dunlop, M.E. and Muggli, E.E. 2000. Small heat shock protein alteration provides a mechanism to reduce mesangial cell contractility in diabetes and oxidative stress. Kidney Int., 57(2):464–475.

Ermak, G., Cheadle, C., Becker, K.G., Harris, C.D. and Davies, K.J. 2004. DSCR1(Adapt78) modulates expression of SOD1. FASEB J., 18(1):62–9.

Feo, S., Arceri, D., Piddini, E., Passantino, R. and Giallongo, A. 2000. ENO1 gene product binds to the c-myc promoter and acts as a transcriptional repressor: relationship with Myc promoter-binding protein 1 (MBP-1). FEBS Lett., 473:47–52.

Fiessinger, F., Rook, J.J. and Duguet, J.P. 1985. Alternative methods for chlorination. Sci. Total Environ., 47:299–315.

Giri, U., Iqbal, M. and Athar, M. 1999. Potassium bromate (KBrO3) induces renal proliferative response and damage by elaborating oxidative stress. Cancer Lett., 135:181–188.

International Agency for Research on Cancer (IARC) 1986. Potassium bromate. IARC Monograph Evaluating Carcinogenic Risk to Humans, 40:207–220.

Jensen, M.R., Factor, V.M., Fantozzi, A., Helin, K., Huh, C.G. and Thor-geirsson, S.S. 2003. Reduced hepatic tumor incidence in cyclin G1-deficient mice. Hepatology, 37:862–870.

Kimura, S.H., Ikawa, M., Ito, A., Okabe, M. and Nohjima, H. 2001. Cyclin G1 is involved in G2/M arrest in response to DNA damage and in growth control after damage recovery. Oncogene, 20(25): 3290–3300.

Kondo, T., Nakamura, N., Suzuki, K., Murata, S., Muramatsu, A., Kawaoi, A. and Katoh, R. 2003. Expression of human pendrin in diseased thyroids. J. Histochem. Cytochem., 51:167–173.

Kurokawa, Y., Maekawa, M., Takahashi, M. and Hayashi, Y. 1990. Toxicity and carcinogenicity of potassium bromate—a new renal carcinogen. Environ. Health Perspect., 87:309–335.

Kurokawa, Y., Matsushima, Y., Takamura, N., Imazawa, T. and Hayashi, Y. 1987. Relationship between the duration of treatment and the incidence of renal cell tumors in male F344 rats administered potassium bromate. Jpn. J. Cancer Res., 78:358–364.

Kurokawa, Y., Aoki, S., Matsushima, Y., Takamura, N., Imazawa, T. and Hayashi, Y. 1986a. Dose-response studies on the carcinogenicity of potassium bromate in F344 rats after long-term oral administration. J. Natl. Cancer Inst., 77:977–982.

Kurokawa, Y., Takayama, S., Konishi, Y., Hiasa, Y., Asahina, S., Takahashi, M., Maekawa, A., Hayashi, Y. 1986b. Long-term in vivo carcinogenicity tests of potassium bromate, sodium hypochlorite, and sodium chlorite conducted in Japan. Environ. Health Perspect., 69:221–235.

Kurokawa, Y., Hayashi, Y., Maekawa, A., Takahashi, M., Kokubo, T. and Odashima, S. 1983. Carcinogenicity of potassium bromate administered orally to F344 rats. J. Natl. Cancer Inst., 71:965–972.

Laflamand, F., Mazars, A., Prunier, C., Bertrand, F., Kornprost, M., Gallée S, Roman-Roman, S. and Cherqui, G. 2001. Afti, A. Smad7 inhibits the survival nuclear factor kappaB and potentiates apoptosis in epithelial cells. Oncogene, 20:879–884.
Kidney Toxicogenomics of Chronic Potassium Bromate Exposure in F344 Male Rats

Lasorella, A., Iavarone, A. and Israel, M.A. 1996. Id2 specifically alters regulation of the cell cycle by tumor suppressor proteins. *Mol. Cell. Biol.*, 16:2570–2578.

Li, C. and Wong, W.H. 2001a. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. *Proc. Natl. Acad. Sci. U.S.A.*, 98:31–36.

Li, C. and Wong, W.H. 2001b. Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application. *Genome Biol.*, 2(8):research0032.1–research0032.11.

Lin, H.Y., Michtalik, H.J., Zhang, S., Andersen, T.T., Van Riper, D.A., Davies, K.K., Ernak, G., Petti, L.M., Nachod, S., Narayan, A.V., Bhatt, N. and Crawford, D.R. 2003. Oxidative and calcium stress regulate DSCR1 (Adapt78/MCIP1) protein. *Free Radic. Biol. Med.*, 35(5):528–539.

Mathers, J., Fraser, J.A., McMahon, M., Saunders, R.D., Hayes, J.D. and McLelland, L.I. 2004. Antioxidant and cytoprotective responses to redox stress. *Biochem. Soc. Symp.*, 71:157–176.

Moller, P. and Wallin, H. 1998. Adduct formation, mutagenesis and nucleotide excision repair of DNA damage produced by reactive oxygen species and lipid peroxidation product. *Mutat. Res.*, 410:271–290.

Murata, M., Bansho, Y., Ohta, M., Shinomi, S., Midorikawa, K. and Kawanishi, S. 2001. Requirement of glutathione and cysteine in guanine-specific oxidation of DNA by carcinogenic potassium bromate. *Chem. Res. Toxicol.*, 14(6):678–685.

NCI (National Cancer Institute). 1976. Report on carcinogenesis bioassay of chloroform. Available from NTIS, Springfield, VA. NTIS PB-264018.

Rahman, A., Ahmed, S., Khan, N., Sultana, S. and Athar, M. 1999. Glyceryl trinitrate, a nitric oxide donor, suppresses renal oxidant damage caused by potassium bromate. *Redox. Rep.*, 4:263–269.

Rice-Evans, C. and Burdon, R. 1993. Free radical-lipid interactions and their pathological consequences. *Prog. Lipid. Res.*, 32:71–110.

Rook, J.J. 1974. Formation of halofurans during chlorination of natural waters. *Water Treat Exam.*, 23:234–245.

Sanhueza, J., Valdes, J., Campos, R., Garrido, A. and Valenzuela, A. 1992. Formation of oxyhalides during chlorination of natural waters. *Water Treat Exam.*, 23:234–245.

Sanhueza, J., Valdes, J., Campos, R., Garrido, A. and Valenzuela, A. 1992. Changes in the xanthine dehydrogenase/xanthine oxidase ratio in the rat kidney subjected to ischemia–reperfusion stress: preventive effect of some flavonoids. *Res. Commun. Chem. Pathol. Pharmacol.*, 78(2):211–218.

Scott, D.A., Wang, R., Kremen, T.M., Sheffield, V.C. and Karniski, L.P. 1999. The Pendred syndrome gene encodes a chloride-iodide transport protein. *Nat. Genet.*, 21:440–443.

Sers, C., Hüsman, K., Nazarenko, I., Reich, S., Wiechen, K., Zhanababayeva, B., Adhikari, P., Schroder, K., Gontarewicz, A. and Schafer, R. 2002. The class II tumour suppressor gene H-REV107-1 is a target of interferon-regulatory factor-1 and is involved in IFN gamma-induced cell death in human ovarian carcinoma cells. *Oncogene*, 21:2829–2839.

Shibutani, S., Takeshita, M. and Grollman, A.P. 1991. Insertion of specific bases during DNA synthesis past the oxidation–damaged base 8-oxodG. *Nature*, 349:431–434.

Skubis-Zegadlo, J., Nikodemiska, A., Przytula, E., Mikula, M., Bardadin, K., Ostrowski, J., Wenzel, B.E. and Szarnawka, B. 2005. Expression of pendrin in benign and malignant human thyroid tissues. *Br. J. Cancer*, 93:144–151.

Soleimani, M., Gheeley, T., Petrovic, S., Wang, Z., Amlal, H., Kopp, P. and Burnham, C.E. 2001. Pendrin: an apical Cl-/OH-/HCO3- exchanger in the kidney cortex. *Am. J. Physiol. Renal. Physiol.*, 280:F356–364.

Stuart, R.O., Bush, K.T. and Nigam, S.K. 2001. Changes in global gene expression patterns during development and maturation of the rat kidney. *Proc. Natl. Acad. Sci. U.S.A.*, 98:5649–5654.

Subramanian, A. and Miller, D.M. 2000. Structural analysis of alpha-enoate. Mapping the functional domains involved in down-regulation of the c-myc protooncogene. *J. Biol. Chem.*, 275:5958–5965.

Ueno, H., Oishi, K., Sayato, Y. and Nakamuro, K. 2000. Oxidative cell damage in Kat-sod assay of xohalides as inorganic disfection by-products and their occurrence by ozonation. *Arch. Environ. Contam. Toxicol.*, 38:1–6.

Umemura, T. and Kurokawa, Y. 2006. Etiology of bromate-induced cancer and possible modes of action-studies in Japan. *Toxicology*, 221(2–3):154–157.

Umemura, T, Kitamura Y, Kanki K, Maruyama S, Okazaki K, Imazawa T, Nishimura T, Hasegawa R, Nishikawa A, Hirose M. 2004. Dose-related changes of oxidative stress and cell proliferation in kidneys of male and female F344 rats exposed to potassium bromate. *Cancer Sci.*, 95(5):393–398.

Umemura, T., Takagi, A., Sai, K., Hasegawa, R. and Karakawa, Y. 1998. Oxidative DNA damage and cell proliferation in kidneys of male and female rats during 13-weeks exposure to potassium bromate (KBrO3). *Arch. Toxicol.*, 72:264–269.

United States Environmental Protection Agency (U.S. EPA): 1986. Guidelines for carcinogen risk assessment. *Federal Register*, 51(185):33992–34003.

Wolf, D.C., Crosby, L.M., George, M.H., Kilburn, S.R., Moore, T.M., Miller, R.T. and DeAngelo, A.B. 1998. Time- and dose-dependent development of potassium bromate-induced tumors in male Fischer 344 rats. *Toxicol. Pathol.*, 26(6):724–729.

Wood, M.L., Dizdaroglu, M., Gajewski, E. and Essigmann, J.M. 1990. Mechanistic studies of ionizing radiation and oxidative mutagenesis: genetic effects of a single 8-hydroxyguanine (7-hydro-8-oxoguanine) residue inserted at a unique site in a viral genome. *Biochemistry*, 29(30):7024–7032.

Yamawaki, H and Berk, B.C. 2005. Thioredoxin: a multifunctional anti-oxidant enzyme in kidney, heart and vessels. *Curr. Opin. Nephrol. Hypertens.*, 14(2):149–153.

Yoshino, T., Sato, E., Nakashima, T., Nagashima, W., Teranishi, M.A., Nakayama, A., Mori, N., Murakami, H., Funahashi, H. and Imai, T. 2004. The immunohistochemical analysis of pendrin in the mouse inner ear. *Hear. Res.*, 195:59–16.

Zager, R.A. and Burkhart, K.M. 1998. Differential effects of glutathione and cysteine on Fe2+, Fe3+, H2O2 and myoglobin-induced proximal tubular cell attack. *Kidney Int.*, 53(6):1661–1672.

Additional Files

File name: Oxidoreductase_table.pdf
File format: .pdf
Title of data: Oxidoreductase data table
Description of data: List of differentially expressed oxidoreductase gene expression in kidney from male rats exposed to 20 ppm (low) and 400 ppm (high) potassium bromate in drinking water for 52 wk.

File name: Lipid metabolism_table.pdf
File format: .pdf
Title of data: Lipid metabolism data table
Description of data: List of differentially expressed lipid metabolism gene expression in kidney from male rats exposed to 20 ppm (low) and 400 ppm (high) potassium bromate in drinking water for 52 wk.
File name: Cellular function_table.pdf
File format: .pdf
Title of data: Cellular function table
Description of data: List of differentially expressed cellular function gene expression in kidney from male rats exposed to 20 ppm (low) and 400 ppm (high) potassium bromate in drinking water for 52 wk.
List of differentially expressed lipid metabolism genes in kidney from male rats exposed to 20 ppm (low) and 400 ppm (high) potassium bromate in drinking water for 52 wk. All comparisons were made between the specific treatment group and their corresponding control.

| Gene Symbol | Gene Name | Affymetrix No. | Accession No. | Fold Change |
|-------------|-----------|----------------|---------------|-------------|
| **Low dose** |           |                |               |             |
| APOE        | Apolipoprotein E | 1370862_at NM_138828 | -1.4           |             |
| CEBPB       | CCAAT/enhancer binding protein (C/EBP), beta | 1387087_at NM_024125 | -1.5           |             |
| CHKA        | Choline kinase alpha | 136892_a_at NM_017127 | -1.7           |             |
| CYTP2E1     | Cytochrome P450, family 2, subfamily e1 | 1367871_at NM_031543 | -1.4           |             |
| CYTP4A10    | Cytochrome P450, family 4, subfamily a10 | 1368934_at NM_016999 | -1.4           |             |
| FADS1       | Fatty acid desaturase 1 | 1367857_at NM_053445 | -1.3           |             |
| APOC3       | Apolipoprotein C-III | 1370009_at NM_012501 | -1.6           |             |
| APOAM       | Apolipoprotein M | 1386980_at NM_019373 | -1.2           |             |
| CYP2E1      | Cytochrome P450, family 2, subfamily e1 | 1367871_at NM_031543 | -1.3           |             |
| CYP4A10     | Cytochrome P450, family 4, subfamily a10 | 1368934_at NM_016999 | -1.3           |             |
| EDN1        | Endothelin 1 | 1369519_at NM_012548 | -1.4           |             |
| EHHADH      | 3-hydroxyacyl coenzyme A dehydrogenase | 1368283_at NM_057107 | -1.3           |             |
| EHHADH      | 3-hydroxyacyl coenzyme A dehydrogenase | 1368283_at NM_012548 | -1.4           |             |
| FABP5       | Fatty acid binding protein 5, epidermal | 1370281_at NM_145878 | 1.4           |             |

**High dose**

| Gene Symbol | Gene Name | Affymetrix No. | Accession No. | Fold Change |
|-------------|-----------|----------------|---------------|-------------|
| ACACA2      | Acetyl-Coenzyme A acyltransferase 2 | 1386880_at NM_130433 | -1.2           |             |
| ACSL3       | Acyl-CoA synthetase long-chain family member 3 | 1381777_at NM_057107 | -1.3           |             |
| APOC3       | Apolipoprotein C-III | 1370009_at NM_012501 | -1.6           |             |
| APOAM       | Apolipoprotein M | 1386980_at NM_019373 | -1.2           |             |
| CYTP2E1     | Cytochrome P450, family 2, subfamily e1 | 1367871_at NM_031543 | -1.3           |             |
| CYTP4A10    | Cytochrome P450, family 4, subfamily a10 | 1368934_at NM_016999 | -1.3           |             |
| EHHADH      | 3-hydroxyacyl coenzyme A dehydrogenase | 1368283_at NM_012548 | -1.4           |             |
| HADHSC      | L-3-hydroxyacyl-Coenzyme A dehydrogenase | 1370237_at NM_057186 | -1.3           |             |

*Gene symbols and accession numbers from Affymetrix NetAffx (http://www.affymetrix.com/analysis/index.affx)*
List of differentially expressed cellular function genes in kidney from male rats exposed to 20 ppm (low) and 400 ppm (high) potassium bromate in drinking water for 52 wk. All comparisons were made between the specific treatment group and their corresponding control.

| Gene Symbol | Gene Name                                           | Affymetrix No. | Accession No. | Fold Change |
|-------------|-----------------------------------------------------|----------------|---------------|-------------|
| Low dose    |                                                     |                |               |             |
| Akap12      | A kinase (PRKA) anchor protein (gravin) 12          | 1368869_at     | NM_057103     | -1.8        |
| Arhb        | Ras homolog gene family, member B                   | 1369958_at     | NM_004040     | -1.5        |
| Cespb       | CCAAT/enhancer binding protein (C/EBP), beta        | 1387078_at     | NM_021415     | -1.5        |
| Csf2rb      | Colony stimulating factor 2 receptor, beta 1        | 1369828_at     | NM_133555     | -1.3        |
| Cyp2e1      | Cytochrome P450 family 2, subfamily e1              | 1367871_at     | NM_031543     | -1.4        |
| Dscr1       | Down syndrome critical region homolog 1             | 1388686_at     | NM_153724     | -1.4        |
| Dsipi       | Delta sleep inducing peptide, immunoreactor        | 1367771_at     | NM_031345     | -1.7        |
| Dusp6       | Dual specificity phosphatase 6                      | 1387024_at     | NM_053883     | -1.4        |
| Epim        | Epimorphin                                          | 1372832_at     | NM_012748     | -1.4        |
| F3          | Coagulation factor 3                                | 1369182_at     | NM_013057     | -1.6        |
| Gadd45a     | Growth arrest and DNA-damage-inducible 45 alpha     | 1368947_at     | NM_024127     | -1.4        |
| Hba-a1      | Hemoglobin alpha, adult chain 1                     | 1375519_at     | NM_013096     | -1.3        |
| Hbb         | Hemoglobin beta chain complex                       | 1371102_x_at   | NM_033234     | -1.6        |
| Id2         | Inhibitor of DNA binding 2                          | 1368870_at     | NM_013060     | -1.5        |
| Id3         | Inhibitor of DNA binding 3                          | 1387769_a_at   | NM_013058     | -1.5        |
| Igf3p3      | Insulin-like growth factor binding protein 3        | 1367652_at     | NM_012588     | -1.5        |
| Igf3p6      | Insulin-like growth factor binding protein 6        | 1372168_s_at   | NM_013104     | -2.3        |
| Jun         | v-jun sarcoma virus 17 oncogene homolog             | 1389528_s_at   | NM_021835     | -1.6        |
| Lgmn        | Legumain                                            | 1368430_at     | NM_022226     | -1.3        |
| Mcll        | Myeloid cell leukemia sequence 1                    | 1370141_at     | NM_021846     | -1.6        |
| Pim1        | Serine threonine protein kinase                     | 1374429_at     | NM_017034     | -1.6        |
| Ptgds       | Prostaglandin D2 synthase                           | 1367851_at     | NM_013015     | -1.4        |
| Rgc32       | Response gene to complement 3                       | 1368080_at     | NM_054008     | -1.8        |
| Rhob        | rhoB gene                                           | 1369958_at     | NM_022542     | -1.4        |
| Sgk         | Serum/glucocorticoid regulated kinase               | 1367802_at     | NM_019232     | -1.6        |
| Tieg        | Tgfb inducible early growth response                | 1368650_at     | NM_031135     | -1.4        |
| Txnrd1      | Thioredoxin reductase 1                             | 1369658_at     | NM_031614     | -1.3        |
| Vegfb       | Vascular endothelial growth factor B                | 1380854_at     | AF022952      | -1.3        |
| Xdh         | Xanthine dehydrogenase                              | 1369973_at     | NM_017154     | -1.4        |
| Calca       | Calcitonin/calcitonin-related polypeptide, alpha    | 1370775_a_at   | NM_017338     | 1.4         |
| Ccnd1       | Cyclin D1                                           | 1383075_at     | NM_171992     | 1.3         |
| Dlgh4       | Discs, large homolog 4                             | 1371183_a_at   | NM_019621     | 2.0         |
| Hand1       | Heart and neural crest derivatives transcript 1     | 1370128_at     | NM_021592     | 1.6         |
| Ifng        | Interferon gamma                                    | 1370790_at     | NM_138880     | 1.9         |
| Ms4a2       | Membrane-spanning 4-domains, A2                     | 1369399_at     | NM_012845     | 1.6         |
| Nr1d1       | Nuclear receptor subfamily 1, group D, member 1     | 1370816_at     | NM_145775     | 1.7         |
| Prl1        | Prolactin receptor                                  | 1370384_a_at   | NM_012630     | 1.4         |
| Stat1       | Sialyltransferase 1                                 | 1370907_at     | NM_147205     | 1.4         |
| Vipr1       | Vasoactive intestinal peptide receptor 1            | 1387561_at     | NM_012685     | 1.6         |
Kidney Toxicogenomics of Chronic Potassium Bromate Exposure in F344 Male Rats

| Gene Symbol | Gene Name | Description | Gene Symbol | Gene Name | Description |
|-------------|-----------|-------------|-------------|-----------|-------------|
| Aldh1a1 | Aldehyde dehydrogenase family 1, member A1 | 1387022_at | NM_022407 | -1.2 |
| Calb1 | Calbindin 1 | 1370201_at | NM_031984 | -1.3 |
| Cyp2e1 | Cytochrome P450, family 2, subfamily e1 | 1367871_at | NM_031543 | -1.3 |
| Ddc | Dopa decarboxylase | 1386064_a_at | NM_012545 | -1.5 |
| Dscr1 | Down syndrome critical region homolog 1 | 1388686_at | NM_153724 | -1.3 |
| Dsipi | Delta sleep inducing peptide, immunoreactor | 1367771_at | NM_031345 | -1.7 |
| Edn1 | Endothelin 1 | 1369519_at | NM_012548 | -1.4 |
| Eno1 | Enolase 1, alpha | 1367575_at | NM_012554 | -1.3 |
| F3 | Coagulation factor 3 | 1369182_at | NM_013057 | -1.4 |
| Folh1 | Folate hydrolase | 1387363_at | NM_057185 | -1.6 |
| Hrasls3 | HRAS like suppressor | 1370202_at | NM_017060 | -1.3 |
| Hrg | Histidine-rich glycoprotein | 1368583_a_at | NM_133428 | -2.0 |
| Id2 | Inhibitor of DNA binding 2 | 1368870_at | NM_013060 | -1.5 |
| Madh7 | MAD homolog 7 | 1368896_at | NM_030858 | -1.5 |
| Ptgds | Prostaglandin D2 synthase | 1367851_at | NM_013015 | -1.5 |
| Rgc32 | Response gene to complement 32 | 1368080_at | NM_054008 | -1.7 |
| Sdc4 | Syndecan 4 | 1367721_at | NM_012649 | -1.2 |
| Serpinf1 | Serine (or cysteine) proteinase inhibitor, clade F1 | 1388569_at | NM_177927 | -1.3 |
| Sp3 | Sp3 transcription factor | 1373584_at | AI175114 | -1.6 |
| Ubf | Upstream binding transcription factor, RNA poly I | 1389830_at | AI105117 | -1.3 |
| Yc2 | Glutathione S-transferase Yc2 subunit | 1371089_at | NM_001009920 | -1.2 |

Adams1 | A disintegrin-like and metalloprotease | 1368223_at | NM_024400 | 1.5 |
Adcyap1r1 | Adenylate cyclase activating polypeptide 1 receptor 1 | 1387302_at | NM_133511 | 1.6 |
Agtr2 | Angiotensin II receptor, type 2 | 1369711_at | NM_012494 | 1.5 |
Atr5 | Activating transcription factor 5 | 1372601_at | NM_172336 | 1.7 |
Ccnl | Cyclin G1 | 136764_at | NM_012923 | 1.3 |
Clu | Clusterin | 1367784_a_at | NM_053021 | 1.5 |
Cstl | Cathespin L | 1370244_at | NM_013156 | 1.2 |
Fahp5 | Fatty acid binding protein 5, epidermal | 1370281_at | NM_145878 | 1.4 |
Ghrl | Ghrelin precursor | 1372524_at | NM_021669 | 1.7 |
Grm1 | Glutamate receptor, metabotropic 1 | 1371180_a_at | NM_017011 | 1.7 |
Gstpl | Glutathione-S-transferase, pi 1 | 1388122_at | NM_012577 | 1.3 |
Lta | Lymphotoxin A | 1368722_at | NM_080769 | 1.3 |
Ms4a2 | Membrane-spanning 4-domains, subfamily A2 | 1369399_at | NM_012845 | 1.6 |
Nprl | Nuclear protein 1 "P8" | 1367847_at | NM_053611 | 1.8 |
Plau | Plasminogen activator, urokinase | 1387675_at | NM_013085 | 1.3 |
Ptpc | Protein tyrosine phosphatase, receptor type, C | 1390798_at | BF288130 | 1.5 |
Th | Tyrosine hydroxylase | 1387075_at | NM_012740 | 1.4 |
Tpm3 | Tropomyosin isoform 6 | 1376929_at | NM_057208 | 1.7 |
Ubd | Ubiquitin D | 1368672_at | NM_053299 | 1.7 |
Unc13a | Unc-13 homolog A | 1369330_at | NM_022861 | 2.3 |
Viprl | Vasoactive intestinal peptide receptor 1 | 1387561_at | NM_012685 | 1.8 |

* Gene symbols and accession numbers from Affymetrix NetAffx (http://www.affymetrix.com/analysis/index.affx)
List of significantly altered oxidoreductase gene expression in kidney from male rats exposed to 20 ppm (low) and 400 ppm (high) potassium bromate in drinking water for 52 wk.

| Gene Symbol a | Gene Name a | Affymetrix No. a | Accession No. a | Fold Change |
|---------------|-------------|------------------|-----------------|-------------|
|**Control versus Low**| | | | |
| Adh1 | Alcohol dehydrogenase 1 | 1368021_at | NM_130780 | -1.298 |
| Cox8h | Cytochrome oxidase subunit VIII-H | 1367739_at | NM_012786 | -1.888 |
| Cyp2e1 | Cytochrome P450, family 2, subfamily e1 | 1367871_at | NM_031543 | -1.347 |
| Cyp4a10 | Cytochrome P450, family 4, subfamily a10 | 1368934_at | NM_016999 | -1.338 |
| Fad3l | Fatty acid desaturase 1 | 1367857_at | NM_053445 | -1.333 |
| P4ha1 | Procollagen-proline, alpha1 polypeptide | 1370954_at | NM_172062 | -1.365 |
| Phgdh | 3-phosphoglycerate dehydrogenase | 1367811_at | NM_031620 | -1.525 |
| Sord | Sorbitol dehydrogenase | 1369635_at | NM_017052 | -1.437 |
| Txnrd1 | Thioredoxin reductase 1 | 1386958_at | NM_031614 | -1.319 |
| Xdh | Xanthine dehydrogenase | 1369973_at | NM_017154 | -1.386 |
|**Control versus High**| | | | |
| Adh1 | Alcohol dehydrogenase 1 | 1368021_at | NM_130780 | -1.396 |
| Aldh1a1 | Aldehyde dehydrogenase family 1, member A1 | 1387022_at | NM_022407 | -1.235 |
| Cyp2e1 | Cytochrome P450, family 2, subfamily e1 | 1367871_at | NM_031543 | -1.341 |
| Cyp4a10 | Cytochrome P450, family 4, subfamily a10 | 1368934_at | NM_016999 | -1.341 |
| Ehhadh | 3-hydroxyacyl coenzyme A dehydrogenase | 1368283_at | NM_133606 | -1.389 |
| Fmol1 | Flavin containing monooxygenase 1 | 1387053_at | NM_012792 | -1.240 |
| Hadhsc | L-3-hydroxyacyl-Coenzyme A dehydrogenase | 1370237_at | NM_057186 | -1.280 |
| Hpd | 4-hydroxyphenylpyruvic acid dioxygenase | 1368188_at | NM_017233 | -1.288 |
| P5 | Thioredoxin domain containing 7 | 1376239_at | NM_001004442 | -1.910 |
| Phgdh | 3-phosphoglycerate dehydrogenase | 1367811_at | NM_031620 | -1.426 |
| Ptgsd | Prostaglandin D2 synthase | 1367851_at | NM_013015 | -1.464 |
| Sord | Sorbitol dehydrogenase | 1369635_at | NM_017052 | -1.320 |
| Suox | Sulfite oxidase | 1370036_at | NM_031127 | -1.387 |

*Gene symbols and accession numbers from Affymetrix NetAffx (http://www.affymetrix.com/analysis/index*